BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Long-term data
presented for the first time today from the SPIRIT III trial, Abbott's U.S.
pivotal trial studying the XIENCE(TM) V Everolimus Eluting Coronary Stent
System, demonstrated that XIENCE V continues to deliver clinically superior
benefits for patients compared to the TAXUS(R) paclitaxel-eluting coronary
stent system. In this trial of more than 1,000 patients, XIENCE V demonstrated
a 45 percent reduction in the risk of major adverse cardiac events (MACE) and
a 32 percent reduction in the risk of target vessel failure (cardiac events
related to the treated vessel) at two years as compared to TAXUS. The SPIRIT
III two-year results were presented by Gregg W. Stone, M.D., principal
investigator of the SPIRIT III trial, during the late-breaking clinical trials
session at EuroPCR 2008.
"Not only did XIENCE V clearly differentiate itself from the TAXUS stent
in the first year after treatment, it has now demonstrated even more positive
effects at two years in the SPIRIT III trial," said Dr. Stone, Columbia
University Medical Center and chairman, Cardiovascular Research Foundation,
New York. "As measured by clinically significant reductions in target vessel
failure and MACE, XIENCE V demonstrated an even greater improvement in patient
outcomes compared to TAXUS at two years than at one year, driven by
numerically lower rates of heart attacks and lower observed rates of
re-intervention of the target lesion. We also saw encouraging trends for lower
observed rates of late and very late stent thrombosis in XIENCE V-treated
patients, especially in those who discontinued dual antiplatelet therapy."
The SPIRIT III trial of 1,002 patients, which is the basis for the pre-
market application of XIENCE V to the U.S. Food and Drug Administration (FDA),
demonstrated the following key results for XIENCE V at two years:
-- A 45 percent reduction in the risk of major adverse cardiac events
(MACE) compared to TAXUS (7.3 percent for XIENCE V vs. 12.8 percent for
TAXUS, p-value=0.004)*. MACE is an important composite clinical measure
of safety and efficacy outcomes for patients, defined as cardiac death,
heart attack (MI), or ischemia-driven target lesion revascularization
(TLR driven by lack of blood supply).
-- A 32 percent reduction in the risk of Target Vessel Failure (TVF,
cardiac events related to the treated vessel) compared to TAXUS
(10.7 percent for XIENCE V vs. 15.4 percent for TAXUS, p-value=0.04)*.
TVF is a composite clinical measure of safety and efficacy outcomes
defined as cardiac death, heart attack (myocardial infarction or MI) or
target vessel revascularization (TVR).
-- A 40 percent reduction in the risk of ischemia-driven target lesion
revascularization (ID-TLR) as compared to TAXUS (4.6 percent for
XIENCE V vs. 7.5 percent for TAXUS, p-value=0.07)*.
-- Low rates of stent thrombosis between one and two years, defined as
very late stent thrombosis, per Academic Research Consortium (ARC)
definition of definite/probable stent thrombosis (0.3 percent for
XIENCE V and 1.0 percent for TAXUS) and per the SPIRIT III protocol
(0.2 percent for XIENCE V and 1.0 percent for TAXUS). The ARC
definitions of stent thrombosis were developed to eliminate variability
in the definitions across various drug eluting stent trials.
"From these results, it is clear that XIENCE V can deliver sustained
benefits to patients over the long term," said John M. Capek, Ph.D., executive
vice president, Medical Products, Abbott. "We continue to be pleased with the
way XIENCE V is performing, with outstanding results that are consistent with
what we have seen throughout the SPIRIT III trial."
About the SPIRIT III Trial
SPIRIT III is a prospective, multi-center, randomized, single-blind,
controlled clinical trial comparing XIENCE V to TAXUS in 1,002 patients
(669 XIENCE V patients, 333 TAXUS patients) with either one or two de novo
native coronary artery lesions. The trial was conducted across 65 academic and
community-based centers in the United States between June 22, 2005 and
March 15, 2006.
The primary endpoint of the SPIRIT III trial was in-segment late loss at
eight months, wherein XIENCE V demonstrated superiority to TAXUS with a
statistically significant 50 percent reduction in late loss (mean, 0.14 mm for
XIENCE V vs. 0.28 mm for TAXUS). In-segment late loss is a measure of vessel
renarrowing. In the co-primary endpoint of TVF at nine months, XIENCE V
demonstrated statistical non-inferiority compared to TAXUS with an observed
20 percent reduction in TVF (7.2 percent for XIENCE V vs. 9.0 percent for
TAXUS).
Additionally, in the pre-specified secondary endpoint of MACE, XIENCE V
demonstrated a 43 percent reduction at nine months (4.6 percent for XIENCE V
vs. 8.1 percent for TAXUS) and a 42 percent reduction in MACE at one year
(6.0 percent for XIENCE V vs. 10.3 percent for TAXUS) compared to TAXUS.
About XIENCE V
The XIENCE V stent system utilizes everolimus, which has been shown to
reduce tissue proliferation in the coronary vessels following stent
implantation, and is based upon the highly deliverable and proven MULTI-LINK
VISION(R) coronary stent platform.
XIENCE V was launched in Europe and other international markets in October
2006. XIENCE V is currently an investigational device in the United States and
Japan, and is under review for approval by the FDA. Abbott expects to gain FDA
approval for XIENCE V in the second quarter of 2008.
Abbott also supplies a private-label version of XIENCE V to Boston
Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System.
PROMUS is designed, studied and manufactured by Abbott and supplied as part of
a distribution agreement between the two companies.
Everolimus is licensed to Abbott by Novartis for use on its drug eluting
stents.
For images of Abbott's XIENCE V stent and other information, please visit
the company's online newsroom at http://www.abbottvascular.com/presskit.
About Abbott Vascular
Abbott Vascular, a division of Abbott, is one of the world's leading
vascular care businesses. Abbott Vascular is uniquely focused on advancing the
treatment of vascular disease and improving patient care by combining the
latest medical device innovations with world-class pharmaceuticals, investing
in research and development, and advancing medicine through training and
education. Headquartered in Northern California, Abbott Vascular offers a
comprehensive portfolio of vessel closure, endovascular and coronary products
that are recognized internationally for their safety and effectiveness in
treating patients with vascular disease.
About Abbott
Abbott (NYSE: ABT) is a global, broad-based health care company devoted to
the discovery, development, manufacture and marketing of pharmaceuticals and
medical products, including nutritionals, devices and diagnostics. The company
employs more than 68,000 people and markets its products in more than
130 countries.
Abbott's news releases and other information are available on the
company's Web site at http://www.abbott.com.
*Event rates are based on Kaplan-Meier estimates; p-values are for
descriptive purposes only.
SOURCE Abbott
bourse
